Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders. The company's lead product candidate, FT516, is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. Fate Therapeutics' pipeline also includes FT596, a multi-antigen targeting NK cell cancer immunotherapy, and FT819, a CAR T-cell therapy for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma. The company was founded in 2007 and is headquartered in San Diego, California.